Fig 1: Translational relevance of IFNγ-induced resistance in FLT3-mutated AML patient blasts(A) Workflow of experimental design: patient blasts obtained from the VUMC Hematology Tissue Repository were cultured for 5–7 days in blast media. A subset of cells was stimulated with IFNγ and barcoded to be combined with control conditions, then analyzed via spectral flow cytometry to assess ontogeny and pSTAT1 response. Additional cells were used for IC50 assays with quizartinib and gilteritinib, proliferation capacity assessments, and AXL expression analysis (see materials and methods).(B) Healthy donor bone marrow embedding of progenitors, dendritic cells, and monocytes (left). Representative patient blast projection onto the donor embedding to determine blast ontogeny (right).(C) Representative histograms of biexponentially transformed pSTAT1 flow cytometry signals in control and 15-min IFNγ-stimulated conditions, shown across the total sample (composite) and ontogeny classifications.(D) Representative IC50 assay performed on patient blasts.(E) Representative western blot analysis of AXL expression in patient blasts under control and IFNγ-exposed conditions for 24 h.(F) Summary map of patient blasts integrating genetic profiles, percent blast ontogeny, z-scores of pSTAT1 SARA scores, IC50 baseline and fold change under IFNγ for quizartinib and gilteritinib, proliferation capacity fold change, and Z scores of AXL baseline expression and 24-h fold change post-IFNγ exposure.(G–I) Correlation plots summarizing key relationships among quantified parameters. Outliers were removed using the interquartile range (IQR) method. Pearson correlation coefficients and p-values are indicated within the plot, and statistical significance was assessed using independent samples t test, where p < 0.05 (∗), p < 0.01 (∗∗), p < 0.001 (∗∗∗), and n.s. = not significant. All quantified data points in this figure are summarized in Data S2.
Supplier Page from BioLegend for Recombinant Human AXL-Fc Chimera (carrier-free)